羸弱补益丸治疗晚期胃癌肿瘤食欲不振-恶病质综合征临床研究  

Clinical effect of Leiruo buyi Pill on cancer anorexia and cachexia syndrome in patients with advanced gastric cancer

作　　者：包华鑫 孙元鹏 BAO Huaxin;SUN Yuanpeng(Department of Oncology,Haian Hospital of Traditional Chinese Medicine,Haian,Jiangsu 226600)

机构地区：[1]江苏省海安市中医院肿瘤内科,江苏海安226600

出　　处：《河北中医》2023年第9期1425-1427,1431,共4页Hebei Journal of Traditional Chinese Medicine

基　　金：江苏省南通市卫生健康委员会2020年度科研课题(编号:QA2020046)。

摘　　要：目的观察羸弱补益丸治疗晚期胃癌肿瘤食欲不振-恶病质综合征(CACS)的临床疗效。方法将122例晚期胃癌CACS患者按照随机数字表法分为2组,对照组61例予复合维生素B片治疗,治疗组61例在对照组治疗基础上加用羸弱补益丸治疗,2组均治疗1个月。比较2组食欲疗效;比较2组不良反应;比较2组生活质量疗效;比较2组治疗前后白细胞介素10(IL-10)、肿瘤坏死因子α(TNF-α)水平变化;比较2组治疗前后体质量指数(BMI);比较2组生存时间。结果治疗组食欲有效率88.52%(54/61),对照组食欲有效率73.77%(45/61),治疗组食欲疗效优于对照组(P<0.05)。治疗组总不良反应率为0,对照组总不良反应率6.56%(4/61),治疗组总不良反应率低于对照组(P<0.05)。治疗组生活质量有效率83.61%(51/61),对照组生活质量有效率63.93%(39/61),治疗组生活质量疗效优于对照组(P<0.05)。2组治疗后IL-10、TNF-α水平均较本组治疗前降低(P<0.05),治疗后治疗组IL-10、TNF-α水平均低于对照组(P<0.05)。2组治疗后BMI均较本组治疗前升高(P<0.05),治疗后治疗组BMI高于对照组(P<0.05)。治疗组生存时间为(7.18±0.56)个月,对照组生存时间为(5.92±0.45)个月,2组生存时间比较差异有统计学意义(P<0.05)。结论羸弱补益丸治疗晚期胃癌CACS临床疗效较高,可改善患者食欲,提高患者生活质量和生存时间,增加患者体质量,应用安全可靠。Objective To observe the clinical effect of Leiruo buyi Pill on cancer anorexia and cachexia syndrome(CACS)in patients with advanced gastric cancer(GC).Methods A total of 122 CACS patients with advanced GC were randomly assigned into the treatment group(n=61)and the control group(n=61).All patients were managed by vitamin b complex tablet,and those in the treatment group were additionally treated with Leiruo buyi Pill.Treated for 1 month,the aim was to compare curative effect of appetite and quality of life(QOL),adverse reactions,interleukin 10(IL-10),tumor necrosis factor-α(TNF-α),body mass index(BMI),as well as survival time.Results The effective rates of appetite(88.52%[54/61]vs 73.77%[45/61]),and QOL(83.61%[51/61]vs 63.93%[39/61])in the treatment group were better than those in the control group(both P<0.05).The adverse reaction rate was significantly lower in the treatment group than that in the control group(0 vs 6.56%[4/61],P<0.05).After treatment,IL-10 and TNF-αin groups were significantly decreased(P<0.05),the decrease were more pronounced in the treatment group compared with the control group(P<0.05).BMI in groups was significantly increased(P<0.05),which in the treatment group was more common(P<0.05).The difference was statistically significant in the survival time between the treatment group and the control group([7.18±0.56]months vs[5.92±0.45]months,P<0.05).Conclusion For CACS patients patients with advanced GC,Leiruo buyi Pill has high clinical efficacy,which can improve appetite,QOL,survival time,BMI,and with safe and reliable application.

关 键 词：胃肿瘤 中药疗法 

分 类 号：R735.2[医药卫生—肿瘤] R283.6[医药卫生—临床医学]